Table 2.
Patients' demographics and clinical characteristics at the time of biopsy for TG.
| Variables | Overall (n = 165) | PU <0.3 g/24 h (n = 40) | PU ≥0.3 g/24 h (n = 125) | P-value* |
|---|---|---|---|---|
| Age at the time of Bx(years) | 50.47 ± 14.82 | 53.05 ± 14.75 | 49.64 ± 14.80 | 0.206 |
| Time from Tx to Bx (months) | 72.00 (2.00, 224.00) |
71.00 (8.00, 195.00) |
72.00 (2.00, 224.00) |
0.989 |
| SBP (mmHg) | 140.01 ± 21.01 | 131.78 ± 16.73 | 142.65 ± 21.61 | 0.004 |
| DBP (mmHg) | 83.74 ± 15.38 | 77.60 ± 12.13 | 85.70 ± 15.82 | 0.001 |
| BMI | 25.19 ± 4.58 | 25.34 ± 4.73 | 25.15 ± 4.55 | 0.817 |
| PTDM | 16 (9.70%) | 1 (2.50%) | 15 (12.00%) | 0.006 |
| Cr at the time of Bx (mg/dL) | 2.67 ± 1.14 | 2.55 ± 1.30 | 2.70 ± 0.97 | 0.439 |
| PU at the time of Bx (g/24 h) | 1.38 ± 1.47 | 0.16 ± 0.70 | 1.77 ± 1.49 | <0.001 |
| Anti-HLA DSA** | 124 (75.15) | 32 (80) | 92 (73.6) | 0.415 |
| ABMR diagnosis | 126 (76.97) | 33 (82.5) | 93 (74.4) | 0.294 |
| Immunosuppressant | ||||
| CNIs (Tac/CyA) | 106/48 | 20/16 | 86/32 | 0.049 |
| MMF/MPA | 89/72 | 23/16 | 66/56 | 0.594 |
| Steroid-free regimen | 32 (19.39) | 8 (20.00) | 24(19.20) | 0.911 |
| Anti-hypertension agents*** | ||||
| ACEI/ARB | 121 (73.33) | 25 (62.5) | 96 (76.8) | 0.075 |
| Beta-adrenergic blockers | 65 (39.39) | 13 (32.5) | 52 (41.6) | 0.305 |
| Calcium channel blockers | 78 (47.27) | 11 (27.5) | 67 (53.6) | 0.004 |
Data are presented as mean ± SD, median (minimum, maximum), or n (%).
P-values indicated group differences for proteinuria <0.3 g/24 h compared with proteinuria ≥ 0.3 g/24 h.
Anti-HLA DSA included either anti-HLA class I or class II or both DSA.
More than 6 consecutive months treatment before biopsy.
Bx, biopsy; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; PTDM, post-transplant diabetes mellitus; HLA, human leukocyte antigen; DSA, donor-specific antibodies; ABMR, antibody-mediated rejection; CNI, calcineurin inhibitor, Tac, tacrolimus; CyA, cyclosporin A; MMF, mycophenolate mofetil; MPA, mycophenolic acid; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker. Bold values indicated statistical significance.